Abstract
The efficacy of a novel triazole, SCH51048, was assessed with a murine model of pulmonary aspergillosis and was compared with those of SCH39304 and itraconazole. A wide range of doses of SCH51048 (5 to 50 mg/kg of body weight) was evaluated. Mortality was significantly delayed in mice treated with doses of 5 mg of SCH51048 per kg or greater in comparison with mortality in controls (P < 0.05). Both SCH51048 and SCH39304 at higher doses (30 and 50 mg/kg) reduced the number of viable Aspergillus fumigatus organisms in lung tissue (P < 0.05). In the present model, itraconazole neither delayed mortality nor significantly reduced the counts in tissue at the doses used. We conclude that SCH51048 is an effective therapy for murine pulmonary aspergillosis.
Full Text
The Full Text of this article is available as a PDF (239.8 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bodet C. A., 3rd, Jorgensen J. H., Drutz D. J. Simplified bioassay method for measurement of flucytosine or ketoconazole. J Clin Microbiol. 1985 Aug;22(2):157–160. doi: 10.1128/jcm.22.2.157-160.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Defaveri J., Salazar M. H., Rinaldi M. G., Graybill J. R. Pulmonary aspergillosis in mice: treatment with a new triazole SCH39304. Am Rev Respir Dis. 1990 Sep;142(3):512–515. doi: 10.1164/ajrccm/142.3.512. [DOI] [PubMed] [Google Scholar]
- Denning D. W., Stevens D. A. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis. 1990 Nov-Dec;12(6):1147–1201. doi: 10.1093/clinids/12.6.1147. [DOI] [PubMed] [Google Scholar]
- Denning D. W., Tucker R. M., Hanson L. H., Stevens D. A. Treatment of invasive aspergillosis with itraconazole. Am J Med. 1989 Jun;86(6 Pt 2):791–800. doi: 10.1016/0002-9343(89)90475-0. [DOI] [PubMed] [Google Scholar]
- Fisher B. D., Armstrong D., Yu B., Gold J. W. Invasive aspergillosis. Progress in early diagnosis and treatment. Am J Med. 1981 Oct;71(4):571–577. doi: 10.1016/0002-9343(81)90208-4. [DOI] [PubMed] [Google Scholar]
- Fraser D. W., Ward J. I., Ajello L., Plikaytis B. D. Aspergillosis and other systemic mycoses. The growing problem. JAMA. 1979 Oct 12;242(15):1631–1635. [PubMed] [Google Scholar]
- Graybill J. R. Future directions of antifungal chemotherapy. Clin Infect Dis. 1992 Mar;14 (Suppl 1):S170–S181. doi: 10.1093/clinids/14.supplement_1.s170. [DOI] [PubMed] [Google Scholar]
- Graybill J. R., Kaster S. R., Drutz D. J. Treatment of experimental murine aspergillosis with BAY n7133. J Infect Dis. 1983 Nov;148(5):898–906. doi: 10.1093/infdis/148.5.898. [DOI] [PubMed] [Google Scholar]
- Hector R. F., Yee E. Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis. Antimicrob Agents Chemother. 1990 Mar;34(3):448–454. doi: 10.1128/aac.34.3.448. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kisch A. L., Maydew R. P., Evan A. P. Synergistic nephrotoxicity of amphotericin B and cortisone acetate in mice. J Infect Dis. 1978 Jun;137(6):789–794. doi: 10.1093/infdis/137.6.789. [DOI] [PubMed] [Google Scholar]
- Patterson T. F., George D., Ingersoll R., Miniter P., Andriole V. T. Efficacy of SCH 39304 in treatment of experimental invasive aspergillosis. Antimicrob Agents Chemother. 1991 Oct;35(10):1985–1988. doi: 10.1128/aac.35.10.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]